Dosage, pharmacological effects and clinical outcomes for bivalirudin in percutaneous coronary intervention

Journal of Invasive Cardiology

Volumn 12, Issue SUPPL. F, 2000, Pages

  Lui, Henry K ^a,b  

^a Medical Specialties Clinic   (United States)

^b Jackson Madison County General Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; DRUG DERIVATIVE; HIRUDIN DERIVATIVE; HIRULOG; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

CONTROLLED CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DOSE RESPONSE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; METHODOLOGY; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTITHROMBINS; CONTROLLED CLINICAL TRIALS; CORONARY THROMBOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; HIRUDINS; HUMANS; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY;

EID: 0034575815     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Gruentzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary artery stenosis. N Engl J Med 1979;301:61-68.
2. Popma JJ, Prpic R, Lansky AJ, et al. Heparin dosing in patients undergoing coronary intervention. Am J Cardiol 1998;82:19P-24P.
3. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998;98:2829-2835.
4. Bittl JA, Chaitman B, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: The final report of the bivalirudin angioplasty study. Am Heart J (submitted)
5. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or post-infarction angina. Hirulog angioplasty study investigators. N Engl J Med 1995;333:764-769.
6. White HD. Direct thrombin inhibition and thrombolytic therapy: Rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial. Am J Cardiol 1998;82:57P-62P.
7. Campbell AR, Mahaffey KW, Lewis BE, et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invas Cardiol 2000;12(Suppl F):14F-19F.
8. Heras M, Chesebro JH, Penny WJ, et al. Importance of adequate heparin dosage in arterial angioplasty in a porcine model. Circulation 1988;78:654-660.
9. Narins CR, Hillegass WB Jr., Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:667-671.
10. McGarry TF Jr., Gottlieb RS, Morganroth J, et al. The relationship between anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J 1992;123:1445-1451.
11. Ferguson JJ, Dougherty KG, Gaos CM, et al. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:1061-1065.
12. Zegers E, Meursing PJ, Verhaught FWA. Routine heparinization during coronary angioplasty. Is it still indicated? J Am Coll Cardiol 2000;35:42.
13. Vainer J, Fleisch M, Gunnes P, et al. Low-dose heparin for routine coronary angioplasty and stenting. Am J Cardiol 1996;78:964-966.
14. Boccara A, Benamer H, Juliard JM, et al. A randomized trial of a fixed high dose vs. a weight-adjusted low dose of intravenous heparin during coronary angioplasty. Eur Heart J 1997;18:631-635.
15. Topol EJ, Califf RM, for the EPIC investigators. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. Lancet 1994;343:881-886.
16. Kereiakes DJ, Lincoff AM, for the EPILOG investigators. Abciximab therapy and unplanned coronary stent deployment: Favorable effects on stent use, clinical outcomes, and bleeding complications. Circulation 1998;97:857-864.
17. Lincoff AM, Tcheng JE, for the PROLOG investigators. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. Am J Cardiol 1997;79:286-291.
18. Weitz J, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin and hirudin of coagulation activation during rt-PA-induced thrombolysis. Blood 1989;74:1025-1030.
19. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy. Proc Natl Acad Sci 1989;86:3619-3623.
20. Kleiman NS. Putting heparin into perspective: Its history and the evolution of its use during percutaneous coronary intervention. J Invas Cardiol 2000;12(Suppl F):20F-26F.
21. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114:489S-510S.
22. Kong DF, Topol EJ, Bittl JA, et al. Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 1999;100:2049-2053.
23. Formanek GR, Frech S, Amplatz K. Arterial thrombus formation during clinical percutaneous catheterization. Circulation 1970;41:833-839.
24. Siegelman SS, et al. Complications of catheter angiography: Study with oscillometry and "pullout" angiograms. Cardiology 1968;91:251-253.
25. Nejad MS, Klapper MA, Steggerda FR, et al. Clotting on the outer surfaces of vascular catheters. Radiology 1968;91:248-250.
26. Wallace S, Medellin H, DeJongh D, et al. Systemic heparinization for angiography. Am J Roentgenol Radium Ther Nucl Med 1972;116:204-209.
27. Bull BS, Korpman RA, Huse WM, et al. Heparin therapy during extracorporeal circulation. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975;69:674-684.
28. Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg 1978;26:231-240.
29. Ogilby JD, Kopelman HA, Klein LW, et al. Adequate heparinization during PTCA: Assessment using activated clotting times. Cathet Cardiovasc Diagn 1989;18:206-209.
30. Pesola GR, Pesola DA. Heparin dosing for percutaneous coronary angioplasty: Use of body surface area to improve initial activated clotting time values. Clin Cardiol 1997;20:1006-1009.
31. Ferguson JJ, Fathy Waly HM, Le D, et al. The effect of body weight and body surface area correction on the distribution of the ACT response to bolus doses of heparin for PTCA. J Invas Cardiol 1998;10:318-322.
32. Wilson JM, Dougherty KG, Ellis KO, et al. Activated clotting times in acute coronary syndromes and percutaneous transluminal coronary angioplasty. Cathet Cardiovasc Diagn 1995;34:1-5.
33. Franke JG, Mildenberger RR, Mackenzie GW, et al. Heparin requirements in coronary angioplasty. Ann New York Acad Sci 1989;556:447-449.
34. Blumenthal RS, Wolff MR, Resar JR, et al. Preprocedural anticoagulation does not reduce angioplasty heparin requirements. Am Heart J 1993;125:1221-1225.
35. Lasky MA, Deutsch E, Bamathan E, et al. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in unstable angina pectoris. Am J Cardiol 1990;65:1425-1429.
36. Laskey MA, Deutsch E, Hirshfield JW Jr., et al. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in patients with coronary arterial thrombus. Am J Cardiol 1990;65:179-182.
37. Hettleman BD, Aplin RL, Sullivan PR, et al. Three days of heparin pretreatment reduces major complications of coronary angioplasty in patients with unstable angina. J Am Coll Cardiol 1990;15:154A.
38. Verheugt FW, Liem A, Zijlstra F, et al. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: Results of the Heparin in Early Patency (HEAP) pilot study. J Am Coll Cardiol 1998;31:289-293.
39. Kong DF, Califf RM. Post-procedure heparin: Boon or burden? Am Heart J 1998;136:183-185.
40. Fail PS, Maniet AR, Banka VS. Subcutaneous heparin in post-angioplasty management: Comparative trial with intravenous heparin. Am Heart J 1993;126:1059-1067.
41. Aquirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC investigators. Circulation 1995;91:2882-2890.
42. Topol EJ, Bonan R, Jewitt D, et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993;87:1622-1629.
43. Lincoff AM. Personal communication.